TTK Healthcare Limited

BSE:507747 Stock Report

Market Cap: ₹20.4b

TTK Healthcare Valuation

Is 507747 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 507747 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 507747 (₹1506.8) is trading above our estimate of fair value (₹149.13)

Significantly Below Fair Value: 507747 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 507747?

Key metric: As 507747 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 507747. This is calculated by dividing 507747's market cap by their current earnings.
What is 507747's PE Ratio?
PE Ratio26.6x
Earnings₹799.43m
Market Cap₹20.42b

Price to Earnings Ratio vs Peers

How does 507747's PE Ratio compare to its peers?

The above table shows the PE ratio for 507747 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average42.1x
590006 Amrutanjan Health Care
42.5xn/a₹20.4b
524164 IOL Chemicals and Pharmaceuticals
20.5x29.2%₹20.0b
524470 Syncom Formulations (India)
55.3xn/a₹18.5b
530199 Themis Medicare
50.3xn/a₹26.5b
507747 TTK Healthcare
26.6xn/a₹20.4b

Price-To-Earnings vs Peers: 507747 is good value based on its Price-To-Earnings Ratio (26.6x) compared to the peer average (42.1x).

Price to Earnings Ratio vs Industry

How does 507747's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
INDSWFTLAB Ind-Swift Laboratories
1.6xn/aUS$71.82m
524652 Ind-Swift
2xn/aUS$13.29m
No more companies available in this PE range
507747 26.6xIndustry Avg. 31.6xNo. of Companies18PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 507747 is good value based on its Price-To-Earnings Ratio (26.6x) compared to the Indian Pharmaceuticals industry average (31.6x).

Price to Earnings Ratio vs Fair Ratio

What is 507747's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

507747 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio26.6x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 507747's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Bal Pharma

₹2.2b

Manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally.

BALPHARMA

₹134.50

7D

11.6%

1Y

27.4%

Caplin Point Laboratories

₹147.7b

Engages in the development, production, marketing, and export of generic pharmaceutical formulations and branded products in India.

CAPLIPOINT

₹1,942.80

7D

-0.4%

1Y

58.1%

Venus Remedies

₹4.0b

Engages in the pharmaceutical business in India and internationally.

VENUSREM

₹298.65

7D

-1.3%

1Y

-16.9%